Podcast Episodes
Back to Search
The Price of Drugs: Investing amid pharma's politics
Drug pricing always comes with political noise, particularly when US elections are concerned. Over the last year, the share prices of pharmaceutical …
8 years, 11 months ago
Boardroom Talk: The risk and reward of UBM's events focus
UBM started life as a newspaper company, and spent most of the last century building up its media and PR operations. But diversification is no longer…
8 years, 11 months ago
Personal Finance Show: 21 April 2017
On this week's Personal Finance Show the team is joined by Rachel Winter, investment manager at Killik & Co. They ask whether you should go for the n…
8 years, 11 months ago
Companies & Markets Show: AIMing High
IC editor John Hughman is joined by small companies guru Simon Thompson and companies editor Ian Smith to discuss why the Aim market remains a stockp…
8 years, 11 months ago
Boardroom Talk: Applied Graphene Materials
Graphene and the hype surrounding atomic chicken wireMark Robinson talks to Gareth Jones (CFO) and Jon Mabbitt (CEO) of Applied Graphene Materials ab…
8 years, 11 months ago
Companies & Markets Show: The great de-rigging
The North Sea, recruiters, Libor, but no mention of Brexit…Deputy companies editor Mark Robinson steps in for John Hughman in this week's look at the…
8 years, 11 months ago
Boardroom Talk: Primary Health Properties
Bringing doctor surgeries into the 21st century, with modern facilities and a wide range of services is going to coast billions of pounds. Ironically…
8 years, 11 months ago
Personal Finance Show: New tax year
In this week's show Monica Tepes, director of investment companies research at Cantor Fitzgerald, joins the personal finance team to explain how inve…
8 years, 11 months ago
Companies & Markets Show: Match-making and break-ups
Companies editor Ian Smith and the team discuss the week's takeover news, Imagination Technologies' Apple contract loss and RPC's bears.
Hosted on Ac…
8 years, 11 months ago
Boardroom Talk: Non-Standard Finance's rocky start
The subprime lender is delivering on the buy-and-build strategy it set out at admission to the main market two years ago. So why has its share price …
8 years, 11 months ago